imatinib mesylate

Type: Keyphrase
Name: imatinib mesylate
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

Recent Research from School of Medicine Highlight Findings in Gastroenterology

By a News Reporter-Staff News Editor at Biotech Week -- New research on Gastroenterology is the subject of a report. According to news originating from Nankoku, Japan , by NewsRx correspondents, research stated, "Most gastrointestinal stromal tumors (GIST) ... [Published HispanicBusiness.com - Apr 17 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

Method of optimizing the treatment of Philadelphia-positive leukemia with imatinib mesylate

The present invention relates to a method of treating Philadelphia-positive leukemia (Ph+ leukemia), in a particular chronic myeloid leukemia (CML), in a human patient population. More specifically, the present invention pertains to a method of treating ... [Published Free Patents Online - Apr 15 2014]
First reported Apr 14 2014 - Updated Apr 15 2014 - 2 reports

Novartis Sues Dr Reddy's Labs Over Patent Infringement

Novartis Pharmaceuticals Corporation moved the District Court of Delaware, US against city-based Dr Reddy’s Laboratories Ltd (DRL) for alleged infringement of its patents.According to Novartis, DRL filed an Abbreviated New Drug Application (ANDA) with ... [Published New Indian Express - Apr 15 2014]
First reported Apr 10 2014 - Updated Apr 10 2014 - 2 reports

Patent Issued for Absorbable Coating for Implantable Device

By a News Reporter-Staff News Editor at Biotech Week -- A patent by the inventors Kleiner, Lothar W. ( Los Altos, CA ); Hossainy, Syed F. A. ( Hayward, CA ); Trollsas, Mikael ( San Jose, CA ); Pacetti, Stephen D. ( San Jose, CA ), filed on March 31, 2010 ... [Published HispanicBusiness.com - Apr 10 2014]
First reported Mar 27 2014 - Updated Mar 27 2014 - 1 reports

Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia ...

The FIP1L1-PDGFRA rearrangement results in constitutive activation of the tyrosine kinase PDGFRA. Neoplasms harboring this rearrangement are responsive to imatinib mesylate at doses much lower than those recommended for the treatment of chronic myelogenous ... [Published 7thSpace - Mar 27 2014]
First reported Mar 14 2014 - Updated Mar 14 2014 - 1 reports

BreastMark: Transcriptomic Datasets and Breast Cancer Outcome

Reis-Filho JS, Pusztai L: Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 2011, 378:1812-1823.Ali S, Coombes RC: Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer ... [Published General Medicine eJournal - Mar 14 2014]
First reported Mar 12 2014 - Updated Mar 12 2014 - 1 reports

Antibody-based arrays for detecting multiple signal transducers in rate circulating cells

The present invention provides antibody-based arrays for detecting the activation state and/or total amount of a plurality of signal transduction molecules in rare circulating cells and methods of use thereof for facilitating cancer prognosis and diagnosis ... [Published PharmCast - Mar 12 2014]
First reported Mar 10 2014 - Updated Mar 10 2014 - 1 reports

Final Frontiers Of The War On Cancer: PD-1 And T-Cells

SummaryCancer immunotherapy or “Immuno-oncology” has become a highly prioritized area of research and development for the pharmaceutical industry. The current data regarding the checkpoint inhibitors is quite remarkable when compared to historical drugs ... [Published Seeking Alpha - Mar 10 2014]
First reported Jan 05 2014 - Updated Jan 05 2014 - 1 reports

Methods and compositions for targeting agents into and across the blood-brain barrier and other endothelial cell microvascular barriers

The present invention relates to nucleic acids and polypeptides encoded thereby, whose expression is modulated in brain microvascular endothelial cells undergoing early dynamic inflammation-induced changes in blood-brain bather functionality. Such polypeptides ... [Published PharmCast - Jan 05 2014]
First reported Jan 03 2014 - Updated Jan 03 2014 - 1 reports

BSE Healthcare index gains 22.6% during 2013, index crosses 10,000 mark

The Indian pharmaceutical stocks remained in limelight during the year 2013 despite quality problems, forex losses, interest burden and Drug Price Controlled Order (DPCO). The pharma stock moved up slowly but continuously during the year with better top ... [Published PharmaBiz - Jan 03 2014]

Quotes

...According to news originating from Nankoku, Japan , by NewsRx correspondents, research stated, "Most gastrointestinal stromal tumors (GIST) are caused by oncogenic KIT or platelet-derived growth factor receptor activation, and the small molecule kinase inhibitor imatinib mesylate is an effective first-line therapy for metastatic or unresectable GIST. However, complete remissions are rare and most patients ultimately develop resistance, mostly because of secondary mutations in the driver oncogenic kinase."
"In some embodiments, optionally in combination with the various embodiments above, enhancing the degradation rate of the coating comprises a step selected from: i) prolonged e-beaming, multiple e-beaming post coating, e-beaming at a lower dose rate for a total longer time under the beam, or e-beaming at room temperature; ii) higher temperature treatment of a coated implantable device for longer time drying in a high humidity environment prior to vacuum/conventional drying; iii) decreasing the BHT content in the coating if the coating comprises BHT; iv) adding lactide monomers and/or oligomers in the coating; v) adding --COOH terminated oligomers of D,L-PLA in the coating; vi) sterilization by gamma radiation at the same dose (i e. 31 kGy) as would be used for e-beam; vii) adding in the coating a plasticizer selected from ethyl lactate, DMSO, NMP, and benzyl benzoate so as to lower the glass transition temperature (T.sub.g) of the coating to accelerate degradation; viii) adding a hygroscopic additive in a coating; ix) adding micronized NaO.sub.2 or KO.sub.2, or superoxide salts in the coating; x) adding more stannous octoate to bring its level up to the maximum level allowed by the material specification. xi) adding LMW D,L-PLA with a MW tuned to degrade within 3 to 6 months; xii) forming micro-porous D,L-PLA coating by a process of controlled phase inversion kinetics; and xiii) any combination of step i)-xii)."

More Content

All (14) | News (13) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (1) | Press Releases (0)
sort by: Date | Relevance
Recent Research from School of Medicine Highlig... [Published HispanicBusiness.com - Apr 17 2014]
Method of optimizing the treatment of Philadelp... [Published Free Patents Online - Apr 15 2014]
Novartis Sues Dr Reddy's Labs Over Patent Infri... [Published New Indian Express - Apr 15 2014]
DRL in legal tangle for Novartis’ Gleevec drug [Published Financial Chronicle - Apr 14 2014]
Patent Issued for Absorbable Coating for Implan... [Published HispanicBusiness.com - Apr 10 2014]
BOSTON SCIENTIFIC : Patent Issued for Tailored ... [Published 4 Traders - Apr 10 2014]
Discovery of imatinib-responsive FIP1L1-PDGFRA ... [Published 7thSpace - Mar 27 2014]
BreastMark: Transcriptomic Datasets and Breast ... [Published General Medicine eJournal - Mar 14 2014]
Antibody-based arrays for detecting multiple si... [Published PharmCast - Mar 12 2014]
Final Frontiers Of The War On Cancer: PD-1 And ... [Published Seeking Alpha - Mar 10 2014]
Methods and compositions for targeting agents i... [Published PharmCast - Jan 05 2014]
BSE Healthcare index gains 22.6% during 2013, i... [Published PharmaBiz - Jan 03 2014]
Hope for more options on cancer drug [Published Calcutta Telegraph - Aug 02 2013]
Fact Sheet for SMS Pharmaceuticals Limited [Published Able2Act - May 06 2008]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.